NCT04185168

Isoflavones and Peritoneal Dialysis

Effects of Isoflavones on Hypertension, Serum Concentrations of Fructoseamine and Advanced Glycated End Products in Peritoneal Dialysis Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: National Nutrition and Food Technology Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of this double-blind randomized clinical trial is to determine the effects of isoflavones on serum concentrations of fructoseamine and advanced glycated end products in peritoneal dialysis patients. Forty-four patients from shafa clinic will randomly assign to either isoflavone or placebo group. The patients in isoflavone group will receive 100 mg soy isoflavone (as 2 capsules) daily for 8 weeks, while the placebo group will receive identical placebo. At the baseline and the end of the study,7 ml blood will be collected from each patient after a 12-14-hours fasting and serum concentrations of fructoseamine, carboxymethyl lysine, pentosidine, glucose will be measured. Furthermore, blood pressure measurements will be performed twice with a ten-minute interval between testing

Conditions

• Peritoneal Dialysis

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	soy isoflavone	100 mg soy isoflavone (as 2 tablets)
OTHER	control	2 tablets of placebo

Timeline

• Start date: 2019-11-16
• Primary completion: 2020-01-18
• Completion: 2020-01-18
• First posted: 2019-12-04
• Last updated: 2020-02-06

Locations

1 site across 1 country: Iran